CCN3 and obesity disorder: A previous report demonstrated that global deletion of NOV/CCN3 in mice with HFD exhibited improved glucose tolerance, insulin sensitivity, and metabolic parameters [4], suggesting that NOV/CCN3 is involved in obesity-associated insulin resistance and can be a novel target for obesity management.